CoCites: A citation-based method for searching scientific literature

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.

Alice T Shaw, Benjamin J Solomon, Rita Chiari, Gregory J Riely, Benjamin Besse, Ross A Soo, Steven Kao, Chia-Chi Lin, Todd M Bauer, Jill S Clancy, Holger Thurm, Jean-Francois Martini, Gerson Peltz, Antonello Abbattista, Sherry Li, Sai-Hong Ignatius Ou. Lancet Oncol 2019
Times Cited: 135

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

Jean-Charles Soria, Daniel S W Tan, Rita Chiari, Yi-Long Wu, Luis Paz-Ares, Juergen Wolf, Sarayut L Geater, Sergey Orlov, Diego Cortinovis, Chong-Jen Yu, Maximillian Hochmair, Alexis B Cortot, Chun-Ming Tsai, Denis Moro-Sibilot, Rosario G Campelo, Tracey McCulloch, Paramita Sen, Margaret Dugan, Serafino Pantano, Fabrice Branle, Cristian Massacesi, Gilberto de Castro. Lancet 2017
Times Cited: 614

List of shared articles

Times cited

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
Aaron C Tan, Daniel S W Tan. J Clin Oncol 2022

SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021).
María Martínez-García, Sonia Servitja Tormo, Noelia Vilariño Quintela, Ana Arance Fernández, Alfonso Berrocal Jaime, Blanca Cantos Sánchez de Ibargüen, Sonia Del Barco Berrón, Rosario García Campelo, Regina Gironés Sarrió, Juan Manuel Sepúlveda-Sánchez. Clin Transl Oncol 2022

Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
David J Benjamin, Alyson Haslam, Jenny Gill, Vinay Prasad. Cancer Med 2022

Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
Steven Sun, Yazdi K Pithavala, Jean-François Martini, Joseph Chen. J Clin Pharmacol 2022

Novel targeted therapies for advanced non-small lung cancer.
Omar Abughanimeh, Anahat Kaur, Badi El Osta, Apar Kishor Ganti. Semin Oncol 2022

Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.
Fiorella Calabrese, Federica Pezzuto, Francesca Lunardi, Francesco Fortarezza, Sofia-Eleni Tzorakoleftheraki, Maria Vittoria Resi, Mariaenrica Tiné, Giulia Pasello, Paul Hofman. Int J Mol Sci 2022

Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients.
Christopher Alvarez-Breckenridge, Jordi Remon, Yolanda Piña, Edwin Nieblas-Bedolla, Peter Forsyth, Lizza Hendriks, Priscilla K Brastianos. Am Soc Clin Oncol Educ Book 2022

Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology Report.
Konstantinos Christofyllakis, Ana Raquel Monteiro, Onur Cetin, Igor Age Kos, Alastair Greystoke, Andrea Luciani. J Geriatr Oncol 2022

ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance.
Zhi-Qiong Yu, Meng Wang, Wen Zhou, Meng-Xia Mao, Yuan-Yuan Chen, Na Li, Xiao-Chun Peng, Jun Cai, Zhi-Qiang Cai. J Drug Target 2022

Targeting molecular alterations in non-small-cell lung cancer: what's next?
Rafael López-Castro, Tania García-Peña, Xabier Mielgo-Rubio, Mariona Riudavets, Cristina Teixidó, Noelia Vilariño, Felipe Couñago, Laura Mezquita. Per Med 2022

2020 Innovation-Based Optimism for Lung Cancer Outcomes.
Erin L Schenk, Tejas Patil, Jose Pacheco, Paul A Bunn. Oncologist 2021

Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.
Marie-Julie Nokin, Chiara Ambrogio, Ernest Nadal, David Santamaria. Trends Cancer 2021

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Nasser H Hanna, Andrew G Robinson, Sarah Temin, Sherman Baker, Julie R Brahmer, Peter M Ellis, Laurie E Gaspar, Rami Y Haddad, Paul J Hesketh, Dharamvir Jain,[...]. J Clin Oncol 2021

Systemic Therapy for Mutation-Driven NSCLC.
Lova Sun, Melina E Marmarelis, Corey J Langer. Semin Radiat Oncol 2021

Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations.
David König, Spasenija Savic Prince, Sacha I Rothschild. Cancers (Basel) 2021

Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Jordi Remon, Daniele Pignataro, Silvia Novello, Francesco Passiglia. Cancer Treat Rev 2021

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.
Mathieu Chevallier, Maxime Borgeaud, Alfredo Addeo, Alex Friedlaender. World J Clin Oncol 2021

Lung cancer.
Alesha A Thai, Benjamin J Solomon, Lecia V Sequist, Justin F Gainor, Rebecca S Heist. Lancet 2021

112

Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer.
Pamela Abdayem, David Planchard. Eur Respir Rev 2021

Systemic Therapy for Lung Cancer Brain Metastases.
Alessia Pellerino, Francesco Bruno, Roberta Rudà, Riccardo Soffietti. Curr Treat Options Oncol 2021

Recent advances in lung cancer genomics: Application in targeted therapy.
Neha Pathak, Sindhura Chitikela, Prabhat Singh Malik. Adv Genet 2021

Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.
Yuan Cheng, Tao Zhang, Qing Xu. MedComm (2020) 2021

Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer.
Joan Rou-En Choo, Ross A Soo. Expert Rev Anticancer Ther 2020

An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC.
Viola W Zhu, Yen-Ting Lin, Dong-Wan Kim, Herbert H Loong, Misako Nagasaka, Hao To, Yvonne Li-En Ang, Chan-Young Ock, Nishan Tchekmedyian, Sai-Hong Ignatius Ou,[...]. J Thorac Oncol 2020

Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Miriam Grazia Ferrara, Vincenzo Di Noia, Ettore D'Argento, Emanuele Vita, Paola Damiano, Antonella Cannella, Marta Ribelli, Sara Pilotto, Michele Milella, Giampaolo Tortora,[...]. Cancers (Basel) 2020

Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners.
Mollie Reed, Aimee-Lauren S Rosales, Marc D Chioda, Lindsey Parker, Geeta Devgan, Jacob Kettle. Adv Ther 2020

A user's guide to lorlatinib.
Misako Nagasaka, Yubin Ge, Ammar Sukari, Geetika Kukreja, Sai-Hong Ignatius Ou. Crit Rev Oncol Hematol 2020